Drug Profile

MRT 5005

Alternative Names: MRT-5005

Latest Information Update: 17 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Translate Bio
Class Antifibrotics; RNA
Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cystic fibrosis
New Molecular Entity Yes

Highest Development Phases

Phase I/II Cystic fibrosis

Most Recent Events

14 Sep 2021 Translate Bio has been acquired by Sanofi
19 Mar 2021 Phase I/II RESTORE-CF trial is still ongoing for Cystic fibrosis in USA (Inhalation) (NCT03375047)
17 Mar 2021 Interim efficacy, immunogenicity and adverse events data from a phase I/II trial in Cystic fibrosis released by Translate Bio

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com